002317.SHE Guangdong Zhongsheng Pharmaceutical Co Ltd
- Market cap
- CNY 19.4B
- P/E
- 91.4x
- P/B
- 4.60x
- ROE
- 5.8%
- Dividend yield
- 0.88%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002317.SHE undervalued?
Graham numberThe Graham number of Guangdong Zhongsheng Pharmaceutical Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guangdong Zhongsheng Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Guangdong Zhongsheng Pharmaceutical Co Ltd yet.
Guangdong Zhongsheng Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China. The company offers onradir, Leretevir, compound danshen, Cefixime Dispersible, Pyrazinamide, Ethamibutanol Hydrochloride, Ribavirin, loratadine, and isoniazid tablets; compound thromboplastin series, Zhong Sheng Wan series, and heat-clearing and dampness-removing granules products; NaoShuanTong, Cefadroxil, Rifampicin, and omeprazole enteric-…
Full company profileGuangdong Zhongsheng Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guangdong Zhongsheng Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.69B | 1.96B | 2.36B | 2.53B | 1.90B | 2.43B | 2.68B | 2.61B | 2.47B | 2.52B | 1.96B |
| Gross Profit | 1.18B | 1.15B | 1.45B | 1.61B | 1.24B | 1.62B | 1.73B | 1.53B | 1.33B | 1.42B | 1.08B |
| Operating Income | 463M | 494M | 501M | 381M | -324M | 313M | 374M | 299M | -280M | 321M | 205M |
| EBITDA | 491M | 465M | 576M | 572M | 352M | 462M | 478M | 465M | 323M | 426M | 272M |
| Net Income | 414M | 420M | 436M | 318M | -427M | 278M | 322M | 263M | -299M | 276M | 235M |
| EPS | 0.54 | 0.52 | 0.53 | 0.40 | -0.53 | 0.35 | 0.40 | 0.32 | -0.36 | 0.32 | 0.28 |
| Balance Sheet | |||||||||||
| Total Assets | 4.23B | 4.86B | 5.24B | 5.51B | 4.78B | 4.90B | 5.78B | 6.46B | 5.55B | 5.13B | 5.13B |
| Total Liabilities | 801M | 1.13B | 1.29B | 1.37B | 1.16B | 1.36B | 1.96B | 1.93B | 1.54B | 980M | 962M |
| Shareholders' Equity | 3.39B | 3.71B | 3.90B | 4.07B | 3.52B | 3.48B | 3.70B | 4.36B | 3.91B | 4.06B | 4.07B |
| Cash & Short-term Investments | 1.15B | 1.23B | 929M | 970M | 1.63B | 1.26B | 1.27B | 1.94B | 1.71B | 985M | 858M |
| Total Debt | 72.6M | 438M | 814M | 784M | 713M | 503M | 878M | 720M | 304M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 338M | 370M | 327M | 251M | 139M | 623M | 63.1M | 191M | 338M | 305M | - |
| Capital Expenditure | 141M | 124M | 143M | 128M | 154M | 214M | 268M | 363M | 228M | 316M | 252M |
| Free Cash Flow | 197M | 246M | 183M | 123M | -15.5M | 409M | -205M | -172M | 110M | -11.0M | 593M |
| Ratios | |||||||||||
| ROE | 12.2% | 11.3% | 11.2% | 7.8% | -12.1% | 8.0% | 8.7% | 6.0% | -7.6% | 6.8% | 5.8% |
| ROA | 9.8% | 8.7% | 8.3% | 5.8% | -8.9% | 5.7% | 5.6% | 4.1% | -5.4% | 5.4% | 4.6% |
| Net Profit Margin | 24.5% | 21.4% | 18.4% | 12.6% | -22.5% | 11.4% | 12.0% | 10.1% | -12.1% | 10.9% | 12.0% |
| Debt to Equity | 0.02x | 0.12x | 0.21x | 0.19x | 0.20x | 0.14x | 0.24x | 0.17x | 0.08x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guangdong Zhongsheng Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.88%
- Forward dividend
- 0.20 CNY
- Payout ratio
- 61.8%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 170M | 0.20 | 61.8% |
| 2024 | CNY 171M | 0.21 | - |
| 2023 | CNY 172M | 0.21 | 65.2% |
| 2022 | CNY 162M | 0.20 | 50.2% |
| 2021 | CNY 160M | 0.20 | 57.7% |
| 2020 | CNY 161M | 0.20 | - |
| 2019 | CNY 161M | 0.20 | 50.6% |
| 2018 | CNY 178M | 0.22 | 40.8% |
| 2017 | CNY 161M | 0.20 | 38.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Sep 1, 2015.
Who owns Guangdong Zhongsheng Pharmaceutical Co Ltd
- Insiders 24.66%
- Institutions 17.99%
- Public & others 57.35%
- Shares outstanding 850M
- Free float 616M
Guangdong Zhongsheng Pharmaceutical Co Ltd company profile
- Company name
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Ticker
- 002317.SHE
- ISIN
- CNE100000HW4
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Dec 11, 2009
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,757
- Fiscal year end
- December
- Address
- Information Industry Park, Dongguan, China, 523325
- Phone
- 86 769 8618 8130
- Website
- zspcl.com
About Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China. The company offers onradir, Leretevir, compound danshen, Cefixime Dispersible, Pyrazinamide, Ethamibutanol Hydrochloride, Ribavirin, loratadine, and isoniazid tablets; compound thromboplastin series, Zhong Sheng Wan series, and heat-clearing and dampness-removing granules products; NaoShuanTong, Cefadroxil, Rifampicin, and omeprazole enteric-coated capsules; carbocysteine, Ambroxol Hydrochloride, and Clomastine fumarate oral solutions; sucralfate oral suspension; reba pat film; and Azalastine Hydrochloride, Praprofen, Diquafosol Sodium, and Cyclosporine eye drops. It also focuses on the fields of respiratory antiviral, ophthalmology, cardiovascular and cerebrovascular endocrinology, anti-infection, digestion, and anti-allergy. Guangdong Zhongsheng Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Dongguan, China.
Guangdong Zhongsheng Pharmaceutical Co Ltd management
6- Mr. Yong Hong ChenChairman & President · born 1971
- Ms. Yuchong ZhangVice Chairman & Senior VP · born 1989
- Ms. Chun Hua LongVP, CFO, Financial Director & Director · born 1973
- Mr. Wei YangBoard Secretary · born 1988
- Mr. Rikang LuoVice President · born 1975
- Mr. Shuang LiuVice President · born 1977